Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Solid Tumours 1Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP2C19 × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT03333824 2019-03-25

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
33 enrolled
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡